Novo Nordisk receives FDA approval for basal insulin Awiqli
Novo Nordisk has secured the US Food and Drug Administration (FDA) approval for Awiqli (insulin icodec-abae) injection 700…
Novo Nordisk wins FDA approval for insulin injection for type 2 diabetes
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection…
Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Novo Nordisk A/S Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli®…
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDAAwiqli® offers adults with type…
Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Novo Nordisk A/S Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli®…
Novo Nordisk Shares Face Sustained Decline: Analysis and Outlook – News and Statistics
Mar 20, 2026 Shares of Danish drugmaker Novo Nordisk have been in a full-blown tailspin over the past…
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis Growth – News and Statistics
Mar 18, 2026 According to a report from Yahoo Finance, Pfizer and Novo Nordisk are among the largest…